My Profile

Search abstracts

Lewis Sheiner

Stockholm, Sweden

Montreux, Switzerland

Budapest, Hungary

Lisboa, Portugal

Hersonissos, Crete, Greece

Alicante, Spain

Glasgow, Scotland

Venice, Italy

Athens, Greece

Berlin, Germany

St. Petersburg, Russia

Marseille, France

KÝbenhavn, Denmark

Brugge/Bruges, Belgium

Pamplona, Spain

Uppsala, Sweden

Verona, Italy

Paris, France

Basel, Switzerland

Salamanca, Spain

Saintes, France

Wuppertal, Germany

Glasgow, Scotland

Sandwich, UK

Frankfurt, Germany

Greenford, UK

Paris, France

Basel, Switzerland

Printable version
Thursday June 7
08:00-08:45 Registration and coffee
08:40-09:00 Welcome and Introduction
  James Shannon, Director of Clinical Research and Development, Novartis
  Oral session I Physiologically-Based Pharmacokinetics chair: Amy Racine / Mick Looby
09:00-09:30 Ryosei Leo Kawai Impact of PK variables assessed by physiologically-based PK models
09:30-10:00 Ivan Nestorov Sensitivity analysis of PBPK and PK/PD models
10:00-10:20 Fredrik Jonsson Contributed paper (1): Physiologically based pharmacokinetic modeling in risk assessment - Development of Bayesian population methods
10:20-12:10 Coffee Poster and Software session I
  Posters with even numbers are accompanied by their presenter
  Tutorial   chair: Amy Racine / Mick Looby
12:10-12:50 Joe Schafer Multiple Imputation for Missing data problems
12:50-14:20 Lunch
  Oral session II Disease progression modelling chair: Oscar della Pasqua
14:20-15:00 Paolo Vicini Integrated system models to understand disease status, progression and therapy: case studies
15:00-15:20 Julie Simpson The natural progression of P.falciparum malaria: Investigation of a historical cohort of syphilis patients treated with malariatherapy
15:20-15:40 Mats Karlsson Models for sedation scores in acute stroke patients
15:40-16:00 Nick Holford Auckland bones and summer sun.
16:00-16:20 Tea and Software
  Oral session III Contributed papers chair: Peter Milligan
16:20-16:40 Philip Jacqmin Contributed paper (2): Modeling drug induced changes in biomarkers without using drug concentrations: Introducing the K-PD model
16:40-17:00 Timothy Goggin Contributed paper (3): Population PD(-PK) modeling and clinical trial simulation, characterizing schedule dependence of hematotoxicity and other Phase II trial design features for a new oral anticancer drug
17:00-18:00 Planning of future PAGE meetings & organization
  Coordinated by Mats Karlsson, Pascal Girard, Jakob Schenker, Jean-Louis Steimer
  For all those interested
19:00-24:00 Social Evening 
  at Safranzunft, Gerbergasse (close to Marktplatz), Basel
Friday June 8
  Oral session IV Contributed papers chair: France Mentre
09:00-09:20 Lewis Sheiner Contributed paper (4): Dealing with Missing Data in Longitudinal Studies through Modeling
09:20-09:40 Gordon Graham Contributed paper (5): Bayesian Optimal Design Applied to Mixed Effect Pharmacokinetic Models
09:40-10:00 James Wright Contributed paper (6): Forward selection and other recipes for disaster
10:00-11:50 Coffee Poster and Software session II
  Posters with uneven/odd numbers are accompanied by their presenter
  Oral session V Contributed papers chair: Janet Wade
11:50-12:10 Hui Kimko Contributed paper (7): Iron kinetics: when drug loss by sampling is critical in data analysis
12:10-12:30 Philip Lowe Contributed paper (8): On mechanism based PK/PD modelling for direct drug-ligand binding systems
12:30-12:50 Leon Aarons Contributed paper (9): The role of modelling and simulation in the clinical development of anti-cancer agents
12:50-14:20 Lunch
  Oral session VI Endogenous products/biotech products chair: Rik Schoemaker
14:20-14:40 Niclas Jonsson A mechanism based population PK/PD model of UK-279,276 in healthy volunteers and patients
14:40-15:00 Per-Henrik Zingmark Dose-Concentration-FACS models for the monoclonal antibody ATM-027, developed for the treatment of Multiple Sclerosis
15:00-15:20 Christian Laveille Hormone exposure and effects on Follicle-Stimulating Hormone (FSH) after nasal administration of estradiol in postmenopausal women
  Oral session VII How to manage data around LOQ chair: Leon Aarons
15:40-16:00 Dave Lunn Graphical models and missing data
16:00-16:20 Vincent Duval Contributed paper (10): Influence of LOQ on the PK parameters after an IV bolus dose
16:20-16:40 Ferdie Rombout LOQ, a relic of the past?
16:40-17:00 Concluding remarks/preview PAGE 2002, Paris